The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Caspofungin Fresenius Kabi 50 mg powder for concentrate for solution for infusion



Fresenius Kabi Deutschland GmbHPA2059/005/001

Main Information

Trade NameCaspofungin Fresenius Kabi 50 mg powder for concentrate for solution for infusion
Active SubstancesCaspofungin
Dosage FormPowder for concentrate for solution for infusion
Licence HolderFresenius Kabi Deutschland GmbH
Licence NumberPA2059/005/001

Group Information

ATC CodeJ02AX Other antimycotics for systemic use
J02AX04 caspofungin

Status

License statusAuthorised
Licence Issued02/12/2016
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletNo document available
Public Assessment ReportNo document available
« Back